MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Country |
 USA |
IPO year |
2013 |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
443 M |
Market Cap[1] |
$ 57.1 B |
EBITDA (LTM) |
$ 487 M |
P/E (LTM) |
21.34 |
P/S (LTM) |
6.16 |
EPS (LTM) |
6.16 |
Zoetis is a global leader in animal health and veterinary medicine, providing a wide range of products and services to improve animal health, including medicines, vaccines, diagnostic tests, and animal health management programs. The company was created in 2013 after being spun off from Pfizer Inc., and is headquartered in New Jersey, USA.
Zoetis works with farmers, veterinarians, and other professionals in the livestock and animal health industries around the world. The company is committed to innovation and developing new products and services to improve animal health and provide more effective animal health management. Zoetis is also actively involved in social responsibility, supporting various charitable organizations and programs.
Today, Zoetis has a presence in over 100 countries and serves millions of animals. The company is constantly striving to improve its products and services to meet the needs of its customers and partners.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Alector
ALEC
|
$ 2.19 | -9.77 % | $ 226 M | Nasdaq Global Select Market,SPB | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Cabaletta Bio
CABA
|
$ 3.34 | 0.45 % | $ 3.9 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Codexis
CDXS
|
$ 1.02 | 1.49 % | $ 74.9 M | Nasdaq Global Select Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 3.74 | 3.6 % | $ 1.12 B | Nasdaq Global Select Market |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Cerus Corporation
CERS
|
$ 2.6 | 1.37 % | $ 480 M | Nasdaq Global Market | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Cellectis S.A.
CLLS
|
$ 3.87 | -0.39 % | $ 116 M | Nasdaq Global Market | France |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
CNS Pharmaceuticals
CNSP
|
$ 3.23 | 2.22 % | $ 1.23 M | Nasdaq Capital Market | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Collegium Pharmaceutical
COLL
|
$ 41.75 | 0.19 % | $ 1.32 B | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 36.14 | 1.23 % | $ 3.75 B | Nasdaq Capital Market,SPB | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Amarin Corporation plc
AMRN
|
$ 13.98 | 1.27 % | $ 5.7 B | Nasdaq Global Market |  Irlanda |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
$ 23.77 | 2.99 % | $ 2.91 B | Nasdaq Capital Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
$ 8.41 | -1.87 % | $ 36.4 M | Nasdaq Global Market | USA |
 |
Cardiff Oncology
CRDF
|
$ 1.94 | 0.01 % | $ 130 M | Nasdaq Capital Market | USA |
 |
Curis
CRIS
|
$ 1.1 | -3.51 % | $ 6.94 M | Nasdaq Global Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
CorMedix
CRMD
|
$ 7.16 | 0.42 % | $ 364 M | Nasdaq Global Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
|
Champions Oncology
CSBR
|
$ 6.14 | 3.89 % | $ 83.9 M | Nasdaq Capital Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Citius Pharmaceuticals
CTXR
|
$ 0.72 | -2.34 % | $ 4.84 M | Nasdaq Capital Market | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | USA |
 |
Altimmune
ALT
|
$ 4.21 | -2.32 % | $ 299 M | Nasdaq Global Market | USA |
 |
CEL-SCI Corporation
CVM
|
$ 3.88 | -8.92 % | $ 247 M | NYSE American,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.